Inorganic Polyphosphate—Regulator of Cellular Metabolism in Homeostasis and Disease

Filip Kus 1,2, Ryszard T. Smolenski 2,* and Marta Tomczyk 2,*

1 Laboratory of Molecular Biology, Intercollegiate Faculty of Biotechnology of University of Gdansk and Medical University of Gdansk, 80-307 Gdansk, Poland; kusfi@gumed.edu.pl
2 Department of Biochemistry, Medical University of Gdansk, 80-211 Gdansk, Poland
* Correspondence: rt.smolenski@gumed.edu.pl (R.T.S.); marta.tomczyk@gumed.edu.pl (M.T.)

Abstract: Inorganic polyphosphate (polyP), a simple anionic polymer consisting of even hundreds of orthophosphate units, is a universal molecule present in both simple and complex organisms. PolyP controls homeostatic processes in animals, such as blood coagulation, tissue regeneration, and energy metabolism. Furthermore, this polymer is a potent regulator of inflammation and influences host immune response in bacterial and viral infections. Disturbed polyP systems have been related to several pathological conditions, including neurodegeneration, cardiovascular disorders, and cancer, but we lack a full understanding of polyP biogenesis and mechanistic insights into the pathways through which polyP may act. This review summarizes recent studies that describe the role of polyP in cell homeostasis and show how disturbances in polyP levels may lead to disease. Based on the collected findings, we highlight the possible usage of this polymer as a promising therapeutic tool in multiple pathologies.

Keywords: inorganic polyphosphate; inflammation; neurodegenerative diseases; SARS-CoV-2; cancer

1. Introduction

Inorganic polyphosphate (polyP) is a linear polymer of orthophosphate units covalently linked by high-energy phosphoanhydride bonds, as in adenosine triphosphate (ATP). As an anionic polymer, it carries a negative charge at physiological pH [1]. PolyP is a highly conserved molecule, present in organisms across all living systems, including archaea, bacteria, fungi, plants, and animals [2].

Despite being structurally very simple, the length of the polymer varies across organisms, which often serves as a distinguishing feature. Bacteria produce long-chain polyP that comprises up to 1000 phosphate residues or more, often in the form of large granules called acidocalcisomes. Eukaryotic cells synthesize shorter polyP chains ranging from around 80 P_i units in human platelets to 200 P_i residues in yeast [3]. The enzymes responsible for polyP synthesis in higher eukaryotes have not been fully identified yet [4], as the synthesis of this polymer has been extensively studied mostly in bacteria. Key prokaryotic enzymes involved in polyP metabolism include polyphosphate kinase (PPK), which catalyzes the synthesis of polyP using ATP as a phosphate donor, and exopolyphosphatase (PPX), responsible for polyP degradation to free P_i [5]. Some bacteria, such as Escherichia coli possess one PPK enzyme, others possess two homologs: PPK1 and PPK2 (e.g., Pseudomonas aeruginosa, Francisella tularensis); and some can have neither [6,7]. Interestingly, homologs of PPK have not been found in higher eukaryotes [8].

The physiological role of polyP in bacterial cells has for years been linked to stress response, phosphate storage, and, more recently, protein folding [9–11]. Bacteria elevate polyP synthesis in response to environmental stress conditions, such as amino acid starvation or oxidative stress [12,13]. It has been shown that under stress conditions polyP plays a crucial role in the regulation of bacterial DNA replication [14]. Gross and Konieczny observed inducible proteolysis of replication initiator protein DnaA by Lon protease in
the presence of polyP in a process termed PolyP-induced DnaA proteolysis (PDAP). In mutant *Escherichia coli* cells that lack PPK enzymes (*E. coli* Δppk) and are therefore not able to synthesize polyP, DnaA protein levels remained stable after stress induction [15].

In addition to its principal role in the regulation of stress response, bacterial polyP has been linked to a variety of other functions. Pathogenic bacteria mutants unable to synthesize polyP were defective in motility [16], biofilm formation [17], cell signaling, and production of virulence factors [18], which suggests polyP’s importance for proper cellular functioning and metabolism.

PolyP’s role in eukaryotic cells is not as well described as in prokaryotes. Nonetheless, there is an increasing amount of research that focuses on elucidating how this ancient molecule shapes eukaryotic cell metabolism, both in homeostatic and pathogenic conditions. Thus, this review highlights open questions and presents polyP as a potent regulator of cellular metabolism, not only in healthy cells but also during infections, tumorigenesis, neurodegeneration, and other pathologies.

2. Polyphosphate as a Regulator of Homeostasis in Eukaryotic Cells

PolyP in higher eukaryotes, specifically in mammals, is present in a broad range of tissues. In rodents, it has been found in the brain, heart, kidneys, liver, and lungs [19]. PolyP has also been found in the lysosomes of human fibroblasts, the nucleoli of human myeloma cells, mitochondria, plasma membranes, microsomes, and cytoplasm compartments of various cell types, as well as in the extracellular space, where it can be released by activated platelets and astrocytes [19–23]. PolyP amounts in mammalian cells oscillate in a micromolar range and are considerably lower than those observed in bacteria [24]. The highest concentration of mammalian polyP was described for platelets, where it reaches around 1 mM [25]. High levels were also observed in bone tissue (several hundred µM polyP in osteoblasts) [26].

In the past century, most research has focused on identifying polyP in various mammalian cells, but the role it may serve was only discussed speculatively [20,27,28]. These speculations covered its function as a regulator of lysosomal transmembrane potential, phosphate storage, or as an energy source. The first indications of the substantial regulatory role of polyP in eukaryotic homeostasis have been described by Ruiz and colleagues [25]. They found that granules of human platelets, which are similar to bacterial acidocalcisomes, are rich in polyP that is released upon thrombin stimulation. Smith et al. described how the polyP of platelets exerts a procoagulant effect and triggers a clotting cascade in the presence of factor XII (FXII), and presented polyP as an activator of the contact pathway of blood clotting [29]. The contact pathway (reviewed by Yi Wu [30]) consists of several plasma proteins activated by negatively charged surfaces or anions (like polyP). PolyP binds and activates FXII, triggering the contact pathway, which leads to blood coagulation and proinflammatory response through the production of the bioactive peptide bradykinin. Furthermore, polyP may be incorporated into fibrin and stabilize fibrin clot structure, making it more resistant to fibrinolysis [31]. Procoagulant effects of polyP are also pronounced; it has the ability to inhibit anticoagulant factors such as tissue factor pathway inhibitor (TFPI) released by endothelial cells [32].

In addition to its procoagulant and proinflammatory functions, polyP released from platelets and platelet-rich plasma have been linked with cell proliferation and tissue regeneration. Müller and colleagues showed that polyP promotes the growth and viability of bone marrow-derived mesenchymal stem cells and upregulates the expression of transcription factors responsible for osteogenesis and chondrogenesis, showing the involvement of polyP in bone and cartilage formation/homeostasis [33]. They also showed that calcium–polyP microparticles are taken up by cells via clathrin-dependent endocytosis; thus, polyP in the form of such microparticles can be manufactured and utilized in treatments of osteoarticular pathologies.

Interestingly, polyP can act also as a mediator of signal transmission in the mammalian brain. Astrocytes activated via polyP, similarly to Ca^{2+} activation, release endogenous
polyP which is further cleared from the extracellular space by neuronal uptake, suggesting that polyP acts as a glio- and neurotransmitter \[23,34\]. PolyP mediates communication between astrocytes by binding to purinergic receptors P2Y\(_1\) in the brainstem \[23\]. P2Y receptors are G protein-coupled receptors, widely distributed within the cells of the human body \[35\]. They are activated by extracellular nucleotides and mediate a myriad of signaling cascades involved in cell development, proliferation, and also immune regulation and inflammation \[36,37\]. PolyP binding to astroglial P2Y\(_1\) results in an increase in central sympathetic activity, stimulates breathing, and raises arterial blood pressure in vivo in rats \[23\]. Furthermore, several studies have demonstrated polyP as a mediator of proteostasis (reviewed by Xie and Jakob \[38\]), suggesting a substantial role of polyP in neurodegenerative disorders. Protein aggregation and production of insoluble fibers called amyloid fibrils are the foundation of neuro-diseases such as Alzheimer’s or Parkinson’s diseases. The intermediates preceding mature fibril formation, such as oligomers and protofibrils, accumulate in the extracellular space (and synapses) and alter cell communication, mitochondrial function, eventually triggering apoptosis \[39\]. PolyP has been shown to act neuroprotectively and abrogate the neurotoxic activity of improperly aggregated amyloid β-peptides/proteins and Tau protein which are responsible for the onset of Alzheimer’s disease \[40\]. Furthermore, polyP levels have been shown to shrink significantly in the brain with aging \[41\], when neurodegenerative disorders are most to likely to occur. Figure 1 collects and presents the activity of polyP in different tissues of the human body.

**Figure 1.** Polyphosphate (polyP) regulates a variety of processes in different tissues in the human organism. In bone tissue, polyP stimulates osteogenesis and chondrogenesis, and promotes the growth and differentiation of bone marrow-derived mesenchymal stem cells (MSCs). In the brainstem, it can be taken up by activated astrocytes and act as a mediator of signal transmission. In the cardiovascular system, polyP can be released within extracellular vehicles by activated platelets, where it activates the contact pathway of blood clotting, stabilizes fibrin clot structure, and mediates proinflammatory responses by activating endothelial cells (ECs).
PolyP in Mitochondrial Homeostasis and Cell Energetics

It is well known that mitochondrial dysfunction might be another critical factor and common feature in neurodegeneration [42]. Recently, Angelova and colleagues showed that approximately 40% of cellular polyP in astrocytes resides in mitochondria [43], where it regulates mitochondrial activity and calcium handling [44]. PolyP in mitochondria acts as a buffering system and prevents the formation of calcium phosphate insoluble precipitates, thus maintaining mitochondrial calcium homeostasis and sustaining high levels of calcium in the bioavailable form [45,46]. Disrupted calcium homeostasis and a decline in mitochondrial function are hallmarks of aging and, in addition to neurodegeneration, have also been associated with coronary heart disease and diabetes [47]. On the other hand, Abramov et al. showed that a depletion of mitochondrial polyP by expression of yeast PPX in several cell lines (including hepatic carcinoma cells, human embryonic kidney cells, and mouse myoblasts) reduces calcium-dependent mitochondrial permeability transition, a key mechanism underlying necrotic and apoptotic cell death [48,49]. Mitochondrial pores are formed upon stressing stimuli and calcium mishandling and also contribute to the process of neurodegeneration in Parkinson’s, Alzheimer’s, and Huntington’s diseases [50]. Similar results were shown in cardiomyocytes, where polyP depletion also leads to the inhibition of mPTPore (mitochondrial permeability pore) formation. Reduction of polyP in cardiac cells may be cardioprotective, as the formation of mPTPore and dysfunction of mitochondria lead to pathologies in cardiac tissue and irreversible cardiac cell injuries [51]. However, research on cardiac myocytes demonstrated a dual role of polyP, which is directly linked to its chain length. While polyP of 14 phosphates activated mPTPore formation, longer polyP molecules (130 phosphates) suppressed mPTP activity [52]. Seidlmayer et al. hypothesized that such competing actions of polyP may stem from polyP’s chaperone activity and ability to bind proteins involved in mPTPore opening. The authors concluded that mitochondrial polyP chain lengths depend on the metabolic state of these organelles, hence the polyP role in mitochondria should be considered in relation to the function of polyP in cell bioenergetics.

Mitochondria are the key energy producers in cells. Interestingly, Pavlov and colleagues described that mitochondrial polyP play an important role in mammalian energetics [53,54]. They observed dynamic changes in polyP levels in astrocytes that were directly triggered by inhibition or activation of mitochondrial respiration. Inhibition of glycolysis by the addition of iodoacetic acid, which blocked the supply of substrates for mitochondrial respiratory complexes, reduced polyP abundance in mitochondria, suggesting that polyP levels may depend on the activity of the respiratory chain. Confirming this observation, in another study, Nakamura and colleagues observed that degradation of polyP enhances lactic acid fermentation in mice expressing the polyP-degrading PPX enzyme [55]. Their model proposes that elongation of polyP and a subsequent reduction in free intracellular Pi concentration sustains mitochondrial respiration and suppresses anaerobic lactic acid production. In a recently published study, Abramov and his group showed that ATP synthase, the mitochondrial inner membrane enzyme responsible for the formation of ATP, is involved in polyP synthesis similarly to the synthesis of ATP [56]. Using isolated rat brain mitochondria, they showed that polyP production is blocked in the presence of oligomycin, an ATP synthase inhibitor. Moreover, application of ATP before or after oligomycin did not affect polyP concentration, which excludes the possibility of ATP being an intermediate product of polyP synthesis. ATP synthase can also function in the opposite direction, as a proton pump hydrolyzing ATP. The authors observed that in the absence of ATP polyP can by hydrolyzed by ATP synthase, proving that polyP can be utilized by eukaryotic cells as a direct source of energy.

However, polyP is not only synthesized in mitochondria. Significant amounts of this polymer can be found in other structures, including the secretory granules of platelets or lysosomes of other cell types (e.g., fibroblasts and glial cells) [20,25,43]. These observations suggest that other enzymes, not only the mitochondrial ones, should also be involved in polyP biogenesis. Reusch et al. proposed that a plasma membrane calcium pump
(Ca$$^{2+}$$-ATPase) from erythrocytes functions as a polyphosphate kinase due to its ATP/ADP-polyphosphate transferase activities [57]. Some authors have also suggested that multiple enzyme complexes may be involved in the process of polyP formation and that polyP may be a byproduct of several enzymatic reactions [54]. Clarifying the issue of polyP synthesis in eukaryotic cells or finding enzymes responsible for polyP production in other intracellular locations is important to allow for further advances in polyP studies.

PolyP may not only act as a direct energy source but also as a phosphate store. For instance, in bacteria, both ATP and polyP are important phosphoryl donors for NAD kinase, which utilizes this polymer to yield NADP$$^+$$ from NAD$$^+$$; however, eukaryotic NAD kinases use only ATP, suggesting another purpose of polyP in mammalian phosphate-metabolism [58,59]. Indeed, recently, an interesting concept has emerged, in which polyP is proposed as both an energy and phosphate source in the extracellular space. Purines and their derivatives, ATP, ADP, and adenosine are important signaling molecules that act through purinergic receptors. Nucleotides can be released from cells by microvesicles, membrane channels, and transporters, or dying cells, and the extracellular adenosine is generated via adenine nucleotide hydrolysis by plasma membrane nucleotidases [60]. Müller et al. hypothesized that polyP may also participate in extracellular nucleotide generation. They found increases in extracellular ATP and ADP levels after polyP treatment of human sarcoma osteogenic (Saos-2) cells [61]. Moreover, they underlined that incubation of Saos-2 cells with polyP leads to translocation of alkaline phosphatase (ALP) and adenylate kinase (AK) to the cell membrane and further release of these enzymes outside of the cell in extracellular vehicles. Both of these enzymes are involved in the interconversion and dephosphorylation of extracellular nucleotides. The increase in the ATP pool after polyP stimulation can both be utilized in purinergic signaling or as an energy reservoir, especially in tissues that consist of a large extracellular matrix in which only a few cells are embedded (e.g., bone and cartilage) [53]. It would be interesting to further investigate how polyP influences the extracellular purinergic system or whether it acts through purinergic receptors in other tissues. It is well known that disruption to purinergic signaling contributes to the pathophysiology of multiple disorders in the immune system, vasculature, heart, kidneys, lungs, and the brain [62]. Nevertheless, polyP influence has not been investigated in the context of Huntington’s disease, a multi-system disorder which comprises both malfunction of purinergic signaling and mitochondrial dysfunction [63]— crucial polyP-associated metabolic events.

The collected findings highlight polyP as a multifunctional molecule that plays a key role in maintaining proper cellular homeostasis; thus, deteriorations in its intra- or extracellular levels may lead to the development of multiple pathologies. PolyP functions in mitochondrial homeostasis and energetics are presented in Figure 2.
3. Regulatory Role of PolyP in Infection and Inflammation

During infection, bacterial cells must withstand various environmental stresses, including changes in temperature, pH, or exposure to different components of the innate immune system, e.g., antimicrobial peptides [64]. Interestingly, it has been found that factors such as oxidative stress and nutrient limitations may upregulate bacterial polyP synthesis [13,65]. Moreover, Roewe et al. have recently demonstrated that the severity of sepsis induced by *E. coli* infection varies depending on whether bacteria can or cannot synthesize polyP [66]. Mice infected with a wild-type *E. coli* strain capable of polyP synthesis displayed poor survival rates. Survival improved in mice infected with an *E. coli* PPK-deficient strain and those treated with PPX, an enzyme that degrades polyP. Furthermore, polyP effects appear to be chain length-dependent. When authors injected bacteria together with chemically synthesized long-chain polyP (which resembles bacterial polyP) into the peritoneal cavities of mice, accelerated mortality was observed, while no significant difference in mortality was found with co-injection of short-chain polyP and bacteria. The difference in the course of sepsis was a result of a weakened myeloid cell response, in particular, an impaired macrophage phagocytosis of bacteria co-injected with long-chain polyP.

Macrophages are the key components in host defense against bacterial infection. One of the classification systems groups these cells into two subpopulations: M1 and M2 macrophages. Polarization to the M1 phenotype, the *Classically Activated Macrophages*, can be driven by LPS and stimulates host defense response to infection. These macrophages are characterized by high antigen presentation, high expression of proinflammatory cytokines, and higher production of reactive nitrogen or oxygen intermediates [67]. Roewe’s study showed that long-chain polyP can be internalized by macrophages and misdirect their
polarization towards the M2 phenotype, the *Alternatively Activated Macrophages* that play a role in wound-healing and display immunosuppressive features [68]. Macrophages incubated with long-chain polyP showed lower transcription levels of M1 phenotype-associated genes, such as *iNOS*, the transcript of which encodes inducible nitric oxide synthase, which exerts a cytotoxic effect on microorganisms during infection [69], or *CXCL10*, encoding a macrophage-attracting chemokine. Long-chain polyP, but not the short-chain, induced CD206 protein expression, the marker of the M2 phenotype. Moreover, long-chain polyP suppressed the transcript levels of MHC-inducing transcription factors and subsequently reduced MHCII and costimulatory proteins CD80 and CD86 expression, influencing macrophages’ antigen-presenting capacities (this effect, again, was not observed with short-chain polyP). In fact, long-chain polyP modulated the expression of more than 1800 genes regulated by LPS/TLR4 signaling and suppressed the expression of hundreds of interferon-regulated genes in macrophages. In conclusion, the production of polyP may be an evasion strategy for bacteria, allowing them to escape from host innate immune responses.

The immunosuppressive actions of long-chain polyP are surprising when compared to the often documented proinflammatory role of short-chain polyP [70–72]. Chrysan-thopoulou et al. recently reported that short polyP activates neutrophils and stimulates the release of neutrophil extracellular traps (NETs), which are known extracellular structures that can trap, neutralize, and kill bacteria [73,74]. Studies on endothelial cells such as HUVECs demonstrated that platelet-like polyP (with a length of around 70 P) enhances the barrier permeability of endothelial cells (ECs) and stimulates the expression of adhesion molecules, such as VCAM-1, ICAM-1, and E-selectin [71]. These molecules are engaged in leukocyte recruitment and binding to ECs and their expression is up-regulated in response to proinflammatory stimuli, such as cytokines or endotoxins [75]. Moreover, short-chain polyP has been shown to amplify proinflammatory responses by binding to histone H4 and high mobility group box 1 (HMGB1) proteins, which are late mediators of inflammation. PolyP together with H4 and HMGB1 activates pro-inflammatory signaling pathways through the EC surface receptors RAGE and P2Y1, and the subsequent NF-κB pathway [70].

In a recently published follow-up study, Rezaie’s laboratory demonstrated that platelet-like polyP together with HMGB1 can also induce von Willebrand factor (VWF) release from endothelial cells; however, the consequences of this interaction remain undetermined [76]. On the other hand, both studies also examined the influence of long-chain polyP on signaling through EC surface receptors and collected data that showed that bacterial-like polyP amplifies proinflammatory responses even more robustly.

Interesting data also exist showing polyP influence on viral infections. Lorenz et al. reported that polyP displays cytoproteective and antiviral activities in HIV-1 infection. This result may be related to the binding of polyP to both cellular and viral surfaces, hence inhibiting virus adsorption [77]. A recent study by Ferrucci and colleagues demonstrated that platelet-like polyP impairs SARS-CoV-2 infection and replication [78]. PolyP was found to bind to the viral RNA-dependent RNA polymerase (RdRp), a key component of the viral replication and transcription machinery, and to induce its proteasomal degradation. PolyP also bound to the ACE2 receptor in human epithelial cells (hECs) and decreased its abundance in a proteasome-dependent manner. Furthermore, in SARS-CoV-2-infected hECs, polyP treatment reduced the transcript levels of proinflammatory cytokines IFN-γ, IL-6, IL-10, IL-12, and tumor necrosis factor-α. The authors hypothesized that polyP may act through the inhibition of the NF-κB pathway in epithelial cells and modulation of the inflammatory cascades.

Taken together, the detailed mechanism of polyP action on the immune system is complex and not fully understood. Even though bacterial and platelet-derived polyP are homogenous in composition, polymers of different lengths appear to modulate distinct signaling pathways and act through diverse intracellular mechanisms (as presented in Figure 3). Thus, more studies seem to be necessary to clarify the connection between polyP, inflammation, and host response to infection.
The first clues indicating polyP as an interesting factor in cancer biology came from Arthur Kornberg’s and Richard A. Roth’s laboratories in 2003. They found that polyphosphates of various chain lengths regulate the activity of mTOR, an important kinase involved in cell proliferation [79]. mTOR (mammalian target of rapamycin) signaling is commonly activated in tumors and plays a regulatory role in tumorigenesis and cancer development. It controls the pentose phosphate pathway responsible for the formation of pyrimidine and purine rings in nucleotides, which are of high demand in cancer cells [80,81]. Roth et al. demonstrated that polyP stimulates the activity of mTOR to phosphorylate its substrate protein PHAS-I that regulates translation initiation and cell proliferation. This effect was abrogated in engineered MCF-7 cells, a human breast cancer cell line expressing the polyP-degrading PPX enzyme. Importantly, engineered cells were defective in growth and showed reduced response to amino acid- or insulin-stimulated PHAS-I phosphorylation.

4. PolyP in Cancer

The PolyP impact on the immune system is chain length-dependent. Bacterial long-chain polyP has an anti-inflammatory effect on myeloid cells, mainly macrophages, by downregulating the expressions of genes associated with antigen processing and antigen presentation, inhibiting the production and release of proinflammatory cytokines (e.g., CXCL10), and stimulating macrophage polarization towards the anti-inflammatory M2 phenotype. On the other hand, platelet-like short-chain polyP has proinflammatory activity, enhancing barrier permeability, upregulating the expression of the receptors necessary for leukocyte recruitment, and stimulating the release of neutrophil extracellular traps (NETs).

Figure 3. PolyP impact on the immune system is chain length-dependent. Bacterial long-chain polyP has an anti-inflammatory effect on myeloid cells, mainly macrophages, by downregulating the expressions of genes associated with antigen processing and antigen presentation, inhibiting the production and release of proinflammatory cytokines (e.g., CXCL10), and stimulating macrophage polarization towards the anti-inflammatory M2 phenotype. On the other hand, platelet-like short-chain polyP has proinflammatory activity, enhancing barrier permeability, upregulating the expression of the receptors necessary for leukocyte recruitment, and stimulating the release of neutrophil extracellular traps (NETs).
PolyP levels have been found elevated in several primary tumor types, including human bronchioloalveolar adenocarcinoma, invasive ductal adenocarcinoma, small intestine adenocarcinoma, prostate adenocarcinoma, and medulloblastoma [82]. Levels of polyP in human myeloma cells (MCs) (polyP of approximately 75–80 P_i in length) are up to 20 times higher than in other human peripheral blood mononuclear cells. In MCs, polyP concentrates in the nucleoli where it colocalizes with and inhibits the transcriptional activity of RNA polymerase I [21]. Another study observed that nucleolar polyP levels in cancer cells rise in response to cisplatin, one of the most widely used drugs in solid cancer treatment. In these cancer cells, polyP has pro-apoptotic activity, increasing cisplatin-induced cytotoxicity and subsequent stimulation of caspase-mediated apoptosis [83,84]. Anti-tumor activity of polyP has also been described by Han and colleagues [85]. They found that polyP shows anti-angiogenic activity and blocks melanoma cell metastasis. A mouse experimental lung cancer model treated with intravenously delivered polyP had a significantly reduced number of lung metastases, and this observation was attributed to the suppression of tumor-induced neovascularization. PolyP blocks the interaction between bFGF (basic fibroblast growth factor) and its surface receptor, which, in turn, inhibits bFGF-induced endothelial cell capillary-like tube formation, thus preventing angiogenesis [85].

On the other hand, there are data indicating an important role for polyP in cancer-associated thrombosis (CAT). CAT can lead to venous thromboembolism, a condition that includes deep vein thrombosis and pulmonary embolism, which increases early mortality in cancer patients [86,87]. It has been shown that polyP is a critical factor in prostate cancer (PC)-associated thrombosis [88]. Healthy prostate epithelial cells release extracellular vesicles called prostasomes into the prostatic duct lumen. In cancer, during metastasis formation, the transition from epithelial to invasive polarity allows PC cells to release prostasomes to blood [89]. PC cells produce prostasomes that expose long-chain polyP (from 200 to more than 1000 P_i) on their surface and this polyP triggers thrombin formation in a factor XII-dependent manner, which contributes to CAT. The authors suggested that interference with the polyP/FXII coagulation pathway may be safely utilized in antithrombotic therapies [90].

In a recently published study, Boyineni and colleagues convincingly demonstrated that polyP may also act as a source of phosphate energy for cancer cells [82]. It is well known that cancer cells derive energy mainly from glucose and aerobic glycolysis (the Warburg effect). Boyineni et al. observed that polyP levels in brain cancer stem cells (also known as brain tumor-initiating cells—BTICs) significantly decrease under glucose deprivation conditions. In analogy with the previously mentioned Roth et al. study, here also the authors engineered cancer cells to express the PPX enzyme, which severely impaired lung cancer and BITC viability. When compared to healthy radial glial cells, the duration of ATP consumption in BITCs was much longer, but shortened in cancer cells depleted of polyP, indirectly suggesting that polyP is indeed utilized as a source of energy.

In summary, the role of polyP in cancer progression and tumorigenesis is still unclear. Elevated levels of polyP in cancer cells remain in contrast to findings indicating that this polymer has anti-tumor activity (Figure 4). Such data again suggest multiple regulatory mechanisms that polyP may be involved in. Thus, more studies are needed to clarify polyP joint interactions in cancerous cells and to generate mechanistic insights.
Figure 4. PolyP plays a dual role in cancer. On the one hand, it can act pro-tumorigenically by stimulating mTOR signaling or being utilized as a direct source of energy. Moreover, prostasomes of prostate cancer expose polyP on the surface, leading to cancer-associated thrombosis (CAT). On the other hand, polyP has been shown to block RNA polymerase I activity, reduce metastatic spread, and inhibit angiogenesis. PolyP also induces death in cisplatin-treated cancer cells.

5. Perspectives and Conclusions

As presented in this review, numerous signaling pathways might be modulated by polyP; however, we still lack full understanding of the broad effects of polyP on signaling cascades. PolyP has been attributed multiple functions in eukaryotic cells, and, besides activating different signaling pathways, this flexibility may also be linked to its binding properties. PolyP can interact with specific proteins, most probably through ionic interactions [38]. Thus, identifying PolyP-associated proteins, the so-called polyP-ome, may not only shed light on the regulatory pathways with which polyP is involved but also give hints about novel polyP roles that have not been described so far. Nevertheless, the establishment of dedicated high-throughput analytical methods encounters many technical problems. To date, only several studies have aimed to identify the polyP-ome (using protein microarrays and labeled polyP) and successfully found some novel polyP-associated interactions [91,92] (the latter being a preprint). Furthermore, in addition to its ability to bind proteins, polyP has been recently reported to be involved in polyphosphorylation [93]. Polyphosphorylation is a non-enzymatic, post-translational modification, in which polyP...
chains are covalently attached to lysine residues of proteins [94]. This might be yet another important mechanism utilized by polyP to mediate various effects on cellular homeostasis.

Methods of polyP quantification also possess limitations (reviewed in depth by Christ et al. [95]). Briefly, simple PAGE separation or dyes for polyP identification (e.g., polyP can be imaged using DAPI and measuring emission wavelengths at 560 nm) are not accurate enough to assess precise chain length. On the other hand, more sophisticated and powerful methods such as NMR or mass spectrometry allow for precise chain length determination but are more complex and cannot reveal polyP localization in the cell. Novel, enzymatic approaches (coupled with colorimetric Pi detection using either malachite green or ascorbic acid) offer sensitivity in determining polyP concentration but work in a very narrow range of polyP chain length or require careful sample preparation to avoid contamination, which can markedly distort the results [96,97]. To date, there is no one universal method for polyP quantification which would be well-suited for diversified applications.

Besides the complications in the investigation of polyP in basic scientific research, polyP seems to be a molecule with a promising therapeutic potential. PolyP may reduce the neurotoxicity caused by amyloid protofibrils or protect from Ca$^{2+}$-induced mitochondrial dysfunction and thus slow down the process of neurodegeneration [98]. Based on these findings, this polymer might be an important agent during the onset of neurodegenerative disorders, such as Alzheimer’s, Parkinson’s, or Huntington’s diseases. Potentially, as presented earlier, polyP could also be utilized in therapies for tissue regeneration [99], cardiovascular disorders [52], infections [100], or even cancer [101]. A growing body of literature is elucidating polyP's involvement in various pathologies but many open questions remain. Further research is needed to clarify the molecular mechanisms through which polyP regulates cell metabolism and take advantage of polyP as a beneficial therapeutic.

Author Contributions: Conceptualization, F.K. and M.T.; formal analysis, R.T.S. and M.T.; writing—original draft preparation, F.K.; writing—review and editing, R.T.S. and M.T.; visualization, F.K.; supervision, R.T.S. and M.T.; funding acquisition, R.T.S. and M.T. All authors have read and agreed to the published version of the manuscript.

Funding: This research was supported by the National Science Centre in Poland (2016/23/B/NZ4/03877).

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Data sharing not applicable.

Acknowledgments: We would like to acknowledge that the figures were created using the©Biorender platform: biorender.com (last accessed: 14 April 2022).

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Morrissey, J.H.; Choi, S.H.; Smith, S.A. Polyphosphate: An ancient molecule that links platelets, coagulation, and inflammation. Blood 2012, 119, 5972–5979. [CrossRef] [PubMed]

2. Rao, N.N.; Gómez-García, M.R.; Kornberg, A. Inorganic Polyphosphate: Essential for Growth and Survival. Annu. Rev. Biochem. 2009, 78, 605–647. [CrossRef] [PubMed]

3. Kulakovskaya, T.; Pavlov, E.; Dedkova, E.N. (Eds.) Inorganic Polyphosphates in Eukaryotic Cells; Springer International Publishing: Cham, Switzerland, 2016; ISBN 978-3-319-41071-5.

4. Baijal, K.; Downey, M. The promises of lysine polyphosphorylation as a regulatory modification in mammals are tempered by conceptual and technical challenges. BioEssays 2021, 43, 2100058. [CrossRef] [PubMed]

5. Akiyama, M.; Crooke, E.; Kornberg, A. An exopolyphosphatase of Escherichia coli. The enzyme and its ppx gene in a polyphosphate operon. J. Biol. Chem. 1993, 268, 633–639. [CrossRef]

6. Zhang, H.; Ishige, K.; Kornberg, A. A polyphosphate kinase (PPK2) widely conserved in bacteria. Proc. Natl. Acad. Sci. USA 2002, 99, 16678–16683. [CrossRef]

7. Bowlin, M.Q.; Gray, M.J. Inorganic polyphosphate in host and microbe biology. Trends Microbiol. 2021, 29, 1013–1023. [CrossRef]

8. Kulakovskaya, T.; Kulaev, I. Enzymes of Inorganic Polyphosphate Metabolism. In Biomedical Inorganic Polymers; Springer: Berlin/Heidelberg, Germany, 2013; Volume 54, pp. 39–63.
62. From Purines to Purinergic Signalling: Molecular Functions and Human Diseases | Signal Transduction and Targeted Therapy. Available online: https://www.nature.com/articles/s41392-021-00553-z (accessed on 1 January 2022).
63. Tomczyk, M.; Glaser, T.; Slominska, E.; Ulrich, H.; Smolenski, R. Purine Nucleotides Metabolism and Signaling in Huntington’s Disease: Search for a Target for Novel Therapies. Int. J. Mol. Sci. 2021, 22, 6545. [CrossRef]
64. Fang, E.C.; Frawley, E.R.; Tapscott, T.; Vázquez-Torres, A. Bacterial Stress Responses during Host Infection. Cell Host Microbe 2016, 20, 133–143. [CrossRef]
65. Kornberg, A.; Rao, N.N.; Ault-Riché, D. Inorganic Polyphosphate: A Molecule of Many Functions. Annu. Rev. Biochem. 1999, 68, 89–125. [CrossRef]
66. Biswas, I.; Panicker, S.; Cai, X.; Mehta-D’Souza, P.; Rezaie, A.R. Inorganic Polyphosphate Amplifies High Mobility Group Box 1—Mediated Von Willebrand Factor Release and Platelet String Formation on Endothelial Cells. Arter. Thromb. Vasc. Biol. 2017, 38, 112–122. [CrossRef]
67. Lorenz, B.; Leuck, J.; Köhl, D.; Müller, W.E.G.; Schröder, H.C. Anti-HIV-1 Activity of Inorganic Polyphosphates. In The polyphosphate–factor XII pathway drives coagulation in prostate cancer-associated thrombosis. Proc. Natl. Acad. Sci. USA 2003, 100, 11249–11254. [CrossRef] [PubMed]
68. Mosser, D.M.; Edwards, J.P. Exploring the full spectrum of macrophage activation. Nat. Rev. Immunol. 2008, 8, 958–969. [CrossRef] [PubMed]
69. Förstermann, U.; Sessa, W.C. Nitric oxide synthases: Regulation and function. Eur. Heart J. 2012, 33, 829–837. [CrossRef] [PubMed]
70. Wang, L.; Fraley, C.D.; Faridi, J.; Kornberg, A.; Roth, R.A. Inorganic polyphosphate stimulates mammalian TOR, a kinase involved both cellular and animal models. J. Thromb. Haemost. 2012, 10, 1145–1151. [CrossRef]
71. Müller, F.; Mutch, N.; Schenck, W.A.; Smith, S.; Esterl, L.; Spronk, H.M.; Schmidbauer, S.; Gahl, W.A.; Morrissey, J.; Renn, T. Platelet Polyphosphates Are Proinflammatory and Procoagulant Mediators In Vivo. Cell 2009, 139, 1143–1156. [CrossRef]
72. Chrystanthopoulou, A.; Kambas, K.; Stavrides, G.; Struvee, M.; Sharma, A.; Marini, F.; Mann, A.; Smith, S.A.; Kaya, Z.; Stroubl, B.; Mueller, M.; et al. Bacterial polyphosphates interfere with the innate host defense to infection. Nat. Commun. 2020, 11, 4035. [CrossRef]
73. Chrysanthopoulou, A.; et al. Interferon lambda1/IL-29 and inorganic polyphosphate are novel regulators of neutrophil-driven thromboinflammation. J. Pathol. 2017, 243, 111–122. [CrossRef]
74. Ferrucci, V.; Kong, D.-Y.; Qureshi, S.H.; Eissenberg, J.C.; Yang, L.; Rezaie, A.R. Inorganic Polyphosphate: A Molecule of Many Functions. Cell 1999, 93, 955–945. [CrossRef]
75. Ferrucci, V.; Kong, D.-Y.; Asadzadeh, F.; Manthody, C.; Eissenberg, J.C.; Yang, L.; Rezaie, A.R. Inorganic Polyphosphate Amplifies High Mobility Group Box 1—Mediated Von Willebrand Factor Release and Platelet String Formation on Endothelial Cells. Arter. Thromb. Vasc. Biol. 2017, 38, 112–122. [CrossRef]
76. Biswas, I.; Panicker, S.; Cai, X.; Mehta-D’Souza, P.; Rezaie, A.R. Inorganic Polyphosphate Amplifies High Mobility Group Box 1—Mediated Von Willebrand Factor Release and Platelet String Formation on Endothelial Cells. Arter. Thromb. Vasc. Biol. 2018, 38, 1868–1877. [CrossRef]
77. Lorenz, B.; Leuck, J.; Köhl, D.; Müller, W.E.G.; Schröder, H.C. Anti-HIV-1 Activity of Inorganic Polyphosphates. J. Acquir. Immune Defic. Syndr. Hum. Retrovirology 1997, 14, 110–118. [CrossRef]
78. Ferrucci, V.; Kong, D.-Y.; Asadzadeh, F.; Marrone, L.; Boccia, A.; Siciliano, R.; Criscuolo, G.; Anastasio, C.; Quarantelli, F.; Comegna, M.; et al. Long-chain polyphosphates impair SARS-CoV-2 infection and replication. Sci. Signal. 2021, 14, eabe5040. [CrossRef] [PubMed]
79. Wang, L.; Fraley, C.D.; Faridi, J.; Kornberg, A.; Roth, R.A. Inorganic polyphosphate stimulates mammalian TOR, a kinase involved in the proliferation of mammary cancer cells. Proc. Natl. Acad. Sci. USA 2003, 100, 11249–11254. [CrossRef] [PubMed]
80. Moresmann, D.; Park, S.; Hall, M.N. mTOR signalling and cellular metabolism are mutual determinants in cancer. Nat. Cancer 2018, 18, 744–757. [CrossRef] [PubMed]
81. Villa, E.; Ali, E.S.; Sahu, U.; Ben-Sahra, I. Cancer Cells Tune the Signaling Pathways to Empower de Novo Synthesis of Nucleotides. Cancers 2019, 11, 688. [CrossRef] [PubMed]
82. Boyineni, J.; Sredni, S.T.; Margaryan, N.V.; Demirkan, L.; Tye, M.; Johnson, R.; Gonzalez-Nilo, F.; Hendrix, M.J.; Pavlov, E.; Soares, M.B.; et al. Inorganic polyphosphate as an energy source in tumorigenesis. Oncotarget 2020, 11, 4613–4624. [CrossRef]
83. Xie, L.; Rajpurkar, A.; Quares, E.; Taube, N.; Rai, A.S.; Erba, J.; Sliwinski, B.; Markowitz, M.; Jakob, U.; Knoefler, D. Accumulation of Nucleolar Inorganic Polyphosphate Is a Cellular Response to Cisplatin-Induced Apoptosis. Front. Oncol. 2019, 9, 1410. [CrossRef]
84. Ghosh, S. Cisplatin: The first metal based anticancer drug. Bioorg. Chem. 2019, 88, 102925. [CrossRef]
85. Han, K.Y.; Hong, B.S.; Yoon, Y.J.; Yoon, C.M.; Kim, Y.-K.; Kwon, Y.-G.; Gho, Y.S. Polyphosphate blocks tumour metastasis via anti-angiogenic activity. Biochem. J. 2007, 406, 49–55. [CrossRef]
86. Hamza, M.; Moussa, S.A. Cancer-Associated Thrombosis: Risk Factors, Molecular Mechanisms, Future Management. Clin. Appl. Thromb. 2020, 26, 1076026920954282. [CrossRef]
87. Young, A.; Chapman, O.; Connor, C.; Poole, C.; Rose, P.; Kakkar, A.K. Thrombosis and cancer. Nat. Rev. Clin. Oncol. 2012, 9, 437–449. [CrossRef]
88. Nickel, K.F.; Ronquist, G.; Langer, F.; Labberton, L.; Fuchs, T.A.; Bokemeyer, C.; Sauter, G.; Graefen, M.; Mackman, N.; Stavrou, E.X.; et al. The polyphosphate–factor XII pathway drives coagulation in prostate cancer-associated thrombosis. Blood 2015, 126, 1379–1389. [CrossRef] [PubMed]
89. Zijlstra, C.; Stoorvogel, W. Prostasomes as a source of diagnostic biomarkers for prostate cancer. J. Clin. Investig. 2016, 126, 1144–1151. [CrossRef] [PubMed]
90. Nickel, K.F.; Labberton, L.; Long, A.T.; Langer, F.; Fuchs, T.A.; Stavrou, E.X.; Butler, L.M.; Renné, T. The polyphosphate/factor XII pathway in cancer-associated thrombosis: Novel perspectives for safe anticoagulation in patients with malignancies. Thromb. Res. 2016, 141, S4–S7. [CrossRef]

91. Azevedo, C.; Singh, J.; Steck, N.; Hofer, A.; Ruiz, F.A.; Singh, T.; Jessen, H.J.; Saiardi, A. Screening a Protein Array with Synthetic Biotinylated Inorganic Polyphosphate To Define the Human PolyP-ome. ACS Chem. Biol. 2018, 13, 1958–1963. [CrossRef] [PubMed]

92. Krenzlin, V.; Roewe, J.; Struve, M.; Martínez-Negro, M.; Reinhardt, C.; Morsbach, S.; Boßmann, M. Proteome Microarray Screening Identifies Human Polyphosphate-Binding Proteins in the Phosphatidylinositol Signaling Pathway. bioRxiv 2021. [CrossRef]

93. Azevedo, C.; Livermore, T.; Saiardi, A. Protein Polyphosphorylation of Lysine Residues by Inorganic Polyphosphate. Mol. Cell 2015, 58, 71–82. [CrossRef]

94. Docampo, R. Catching protein polyphosphorylation in the act. J. Biol. Chem. 2020, 295, 1452–1453. [CrossRef]

95. Christ, J.J.; Willbold, S.; Blank, L.M. Methods for the Analysis of Polyphosphate in the Life Sciences. Anal. Chem. 2020, 92, 4167–4176. [CrossRef]

96. Christ, J.; Blank, L.M. Enzymatic quantification and length determination of polyphosphate down to a chain length of two. Anal. Biochem. 2018, 548, 82–90. [CrossRef]

97. Pokhrel, A.; Lingo, J.C.; Wolschendorf, F.; Gray, M.J. Assaying for Inorganic Polyphosphate in Bacteria. J. Vis. Exp. 2019, 143, e58818. [CrossRef]

98. Borden, E.A.; Furey, M.; Gattone, N.J.; Hambardikar, V.D.; Liang, X.H.; Scoma, E.R.; Samra, A.A.; D-Gary, L.R.; Dennis, D.J.; Fricker, D.; et al. Is there a link between inorganic polyphosphate (polyP), mitochondria, and neurodegeneration? Pharmacol. Res. 2020, 163, 105211. [CrossRef] [PubMed]

99. Wang, Y.; Li, M.; Li, P.; Teng, H.; Fan, D.; Du, W.; Guo, Z. Progress and Applications of Polyphosphate in Bone and Cartilage Regeneration. BioMed Res. Int. 2019, 2019, 5141204–5141212. [CrossRef] [PubMed]

100. Schepler, H.; Wang, X.; Neufarth, M.; Wang, S.; Schröder, H.C.; Müller, W.E.G. The therapeutic potential of inorganic polyphosphate: A versatile physiological polymer to control coronavirus disease (COVID-19). Theranostics 2021, 11, 6193–6213. [CrossRef] [PubMed]

101. Kulakovskaya, E.V.; Zemskova, M. Inorganic Polyphosphate and Cancer. Biochemistry 2018, 83, 961–968. [CrossRef] [PubMed]